Swiss pharmaceutical giant Novartis has agreed to buy London-based biotech Myricx Bio for up to $1.5bn (£1.1bn) as global drugmakers continue deploying billions into promising biotech firms ahead of an estimated $450bn wave of patent expiries over the next decade. The deal will see Novartis pay $1.1bn upfront, with a further $400m tied to development [...]